Antioxidants, Vol. 14, Pages 1484: BiombalanceTM: A Specific Oligomeric Procyanidin-Rich Grape Seed Extract as Multifunctional Ingredient Integrating Antibacterial, Antioxidant, and Anti-Inflammatory Activities with Beneficial Gut–Brain Axis Modulation
Antioxidants, Vol. 14, Pages 1484: BiombalanceTM: A Specific Oligomeric Procyanidin-Rich Grape Seed Extract as Multifunctional Ingredient Integrating Antibacterial, Antioxidant, and Anti-Inflammatory Activities with Beneficial Gut–Brain Axis Modulation Antioxidants doi: 10.3390/antiox14121484 Authors: Mohamed Mokrani Amandine Brochot Maria C. Urdaci Polyphenols, as natural compounds abundant in plant-derived foods, have been recognised for their human health benefits. This […]
Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats
Rationale: Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, are increasingly utilized in clinical practice due to their efficacy in promoting sustained weight loss following chronic administration. While acute treatment with GLP-1 receptor agonists has been shown to suppress food intake and reward-seeking behaviors in rodent models, the impact of prolonged exposure on preclinical measures […]
First ever GLP-1 implant for pets promises major weight-loss benefits
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis.
Costs of Cutting Weight—An Economic Evaluation of GLP-1 Agonists vs Gastric Bypass
This economic evaluation compares the long-term cost-effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists vs Roux-en-Y gastric bypass.
Eli Lilly plans $6B API plant in Alabama
Eli Lilly will build a $6 billion new facility in Huntsville, Ala., to manufacture active pharmaceutical ingredients for small molecule and peptide medicines, including the company’s oral GLP-1 candidate, orforglipron. The site will support domestic production of therapies and strengthen pharmaceutical supply chains, according to a Dec. 9 news release from the drugmaker. The project is […]
Aeroflow Health and Molina Healthcare Break Down Barriers to Nutrition and Diabetes Care in South Carolina
What You Should Know: – Aeroflow Health has launched a statewide partnership with Molina Healthcare of South Carolina to expand access to virtual nutrition counseling and diabetes self-management education (DSME) for Commercial and Medicare members. – The initiative is built to dismantle persistent access barriers by offering evidence-based metabolic and nutrition care at little to no cost, […]
The 26 Most Important Ideas For 2026
Thank you all so much for reading and subscribing to this newsletter. It’s been an absolute blast whose success in its first six months has tremendously exceeded my expectations. If you’re arriving for the first time and like what you see, please subscribe. A little life update: Last week, my wife delivered our second baby […]
Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes
The GLP-1 RA, semaglutide, significantly reduces epilepsy risk in diabetes, and this protective signal is driven by pathways unrelated to improvements in A1c or body weight. Medscape Medical News
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) from YaoPharma, a subsidiary of China’s leading drugmaker, Shanghai Fosun Pharmaceutical. YP05002 is currently being evaluated in phase I for treating obesity. Once-daily oral small molecule GLP-1 RAs are believed to have the […]
GLP-1 Medications, Such as Ozempic, Zepbound, Show Little Effect on Cancer, Study Shows
WEDNESDAY, Dec. 10, 2025 — A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
Researchers analyzed 48 randomized trials including 94,245 adults who were overweight, obese or had…